TP53 and intrahepatic cholangiocarcinoma: Among the congruent changes, both WHO-5 and ICC recognize the poor prognostic impact of biallelic TP53mut defined by the presence of ≥2 mutations or 1 mutation with the loss of residual wild-type TP53 (TP53wt).